Roivant Sciences prices upsized public offering of 30.7M common shares at $7.50, raising ~$230M gross

Roivant Sciences Ltd.

Offering of 30,666,665 shares priced at $7.50 per share; gross proceeds ~$230M before expenses.
Upsized from initial 26,666,666 shares; underwriters' 30-day option exercised in full.
Bookrunners: Goldman Sachs, SVB Securities, Cowen, Cantor Fitzgerald.
Shares sold by Roivant; offering closed February 7, 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Roivant Sciences Ltd. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co. valued at approximately $230 million (effective 2023-02-02).

Action: entry
Agreement: underwriting
Counterparty: Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co.
Value: approximately $230 million
Effective: 2023-02-02

Exact text from the filing

On February 2, 2023, Roivant Sciences Ltd. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co. (the “Representatives”), as the representatives of the underwriters named therein, relating to the issuance and sale in an underwritten offering (the “Offering”) of 30,666,665 of the Company’s common shares

View on SEC.gov

197 material agreements filed in the last 30 days. Browse all material agreements →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-23-005030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.